Area of research
Pharmacology · Economics and Econometrics
Research interest
Research interests include Pharmaceutical industry and healthcare, Pharmaceutical Economics and Policy, Health Systems, Economic Evaluations, Quality of Life, and Pharmacovigilance and Adverse Drug Reactions.
Conflicts of interest in submissions and testimonies to an Australian parliamentary inquiry on menopause
Raising the bar for disclosure of industry payments to doctors
Direct-to-consumer advertising: a modifiable driver of overdiagnosis and overtreatment
Most high-income countries ban direct advertising of prescription drugs – why does NZ still allow it?
Semaglutide: a new drug for the treatment of obesity
Time for New Zealand to ban direct-to-consumer advertising of prescription medicines
78 Direct-to-consumer advertising: a modifiable driver of overdiagnosis and overtreatment
Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis
Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study
Hydroxysine initiation following drug safety advisories on cardiac arrhythmias in the UK and Canada:A longitudinal cohort study
Research at the University of Copenhagen (University of Copenhagen) 2022cited by 0position: middle
Over half of clinical practice guidelines use non-systematic methods to inform recommendations: A methods study
A sorry tale of unnecessary secrecy about medicine safety
Industry funding of patient and health consumer organisations: systematic review with meta-analysis
Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States
A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom and the United States ‐ 2007 to 2016
The “Nuts and Bolts” of Opioid Marketing: Promotional Messages to Family Doctors in Sacramento, Vancouver, Montreal, and Toulouse
Information and promotional strategies by pharmaceutical companies for clinicians
Pathways to independence: towards producing and using trustworthy evidence
Comparative Analysis of Medicines Safety Advisories Released by Australia, Canada, the United States, and the United Kingdom
Secret safety warnings on medicines: A case study of information access requests
The impact of post-market regulatory safety advisories on patients, prescribers, and the healthcare system
Information and promotional strategies by pharmaceutical companies for clinicians
The risk of bias in observational studies of exposures (ROBINS-E) tool: concerns arising from application to observational studies of exposures
Industry sponsorship and research outcome: systematic review with meta-analysis
Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries
Medicines Information and the Regulation of the Promotion of Pharmaceuticals
Reconciling a “pleasant exchange” with evidence of information bias: A three-country study on pharmaceutical sales visits in primary care
Industry sponsorship and research outcome
A health app developer’s guide to law and policy: a multi-sector policy analysis
Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?